Your browser doesn't support javascript.
loading
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study.
Ruíz-Borrego, Manuel; Guerrero-Zotano, Angel; Bermejo, Begoña; Ramos, Manuel; Cruz, Josefina; Baena-Cañada, Jose Manuel; Cirauqui, Beatriz; Rodríguez-Lescure, Álvaro; Alba, Emilio; Martínez-Jáñez, Noelia; Muñoz, Montserrat; Antolín, Silvia; Álvarez, Isabel; Del Barco, Sonia; Sevillano, Elena; Chacón, José Ignacio; Antón, Antonio; Escudero, María José; Ruiz, Victoria; Carrasco, Eva; Martín, Miguel.
Afiliación
  • Ruíz-Borrego M; Department of Medical Oncology, H U Virgen del Rocio, Seville, Spain.
  • Guerrero-Zotano A; Department of Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain.
  • Bermejo B; Department of Medical Oncology, H Clinico de Valencia - Universidad de Valencia-CIBERONC, Valencia, Spain.
  • Ramos M; Department of Medical Oncology, Centro Oncologico de Galicia, A Coruña, Spain.
  • Cruz J; Department of Medical Oncology, H U de Canarias, Tenerife, Spain.
  • Baena-Cañada JM; Department of Medical Oncology, H. U. Puerta del Mar, Instituto de Investigación e Innovación Biomédica de Cádiz (INiBICA), Cadiz, Spain.
  • Cirauqui B; Department of Medical Oncology, Badalona Applied Research Group in Oncology (B-ARGO Group), Catalan Institute of Oncology, Badalona, Spain.
  • Rodríguez-Lescure Á; Department of Medical Oncology, H G U de Elche, Alicante, Spain.
  • Alba E; Department of Medical Oncology, Unidad de Oncología Médica Intercentros H. Regional y Universitario Virgen de la Victoria, IBIMA, Malaga, Spain.
  • Martínez-Jáñez N; Department of Medical Oncology, H U Ramon y Cajal, Madrid, Spain.
  • Muñoz M; Department of Medical Oncology, H Clinic i Provincial de Barcelona, Translational Genomics and Targeted Therapeutics, Institut d´Investigacions Biomèdiques Pi I Sunyer-IDIBAPS, Barcelona, Spain.
  • Antolín S; Department of Medical Oncology, Complejo Hospitalario U A Coruña, A Coruña, Spain.
  • Álvarez I; Department of Medical Oncology, H U Donostia, Donostia, Spain.
  • Del Barco S; Department of Medical Oncology, Instituto Catalan de Oncologia de Girona, Hospital Universitario Josep Trueta, Girona, Spain.
  • Sevillano E; Department of Medical Oncology, Centro Integral Oncologico Clara Campal, Madrid, Spain.
  • Chacón JI; Department of Medical Oncology, H. Virgen de la Salud, Toledo, Spain.
  • Antón A; Department of Medical Oncology, IIS Aragón, H U Miguel Servet, Saragossa, Spain.
  • Escudero MJ; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.
  • Ruiz V; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.
  • Carrasco E; GEICAM, Spanish Breast Cancer Group, Madrid, Spain.
  • Martín M; Medical Oncology Department, Instituto de Investigación Sanitaria H. U. Gregorio Marañon, Universidad Complutense, CIBERONC, C/Dr. Esquerdo 46, 28009, Madrid, Spain. mmartin@geicam.org.
Breast Cancer Res Treat ; 177(1): 115-125, 2019 Aug.
Article en En | MEDLINE | ID: mdl-31152327
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Estrógenos / Receptor ErbB-2 Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Breast Cancer Res Treat Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Estrógenos / Receptor ErbB-2 Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Breast Cancer Res Treat Año: 2019 Tipo del documento: Article